161950-67-0

Upstream product

• 186581-53-3 diazomethane 
• 612-35-1 2-Benzylbenzoic acid 
• 493-05-0 isochromane 
• 108-86-1 bromobenzene 
• 591-50-4 iodobenzene 
• 36374-49-9 2-(2-benzylphenyl)acetic acid 
• 108976-72-3 ethyl o-benzylphenylacetate 
• 23450-18-2 2-benzyl-1-bromobenzene 

Downstream Products

• 2327-09-5 5[2'-(benzyl)phenyl]propionic acid 
• 1381986-46-4 tert-butyl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 2292-59-3 3,4-Dihydro-1-phenyl-1H-benzopyran 
• 161950-33-0 (R)-1-(2-(2-(2-benzylphenyl)ethoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester 
• 161950-68-1 2-(2-(2-benzylphenyl)ethoxy)ethanol 

Relevant academic research and scientific papers

Water Loss from Molecular Protonated Ions of Benzyl 2-Phenylether and Derivates

The skeletal rearrangement for water loss is the dominant reaction in the chemical ioinization mass spectrum of benzyl 2-phenylethyl ether.Isotopic distribution obtained for this reaction with specifically labelled derivates have been interpreted in terms of competing five- and six-centered skeletal rearrangements.Chemical substitution of the altermative aromatic rings strtongly influences the balance of the competition.

Flow-vacuum pyrolysis of polycyclic compounds. 27.1 pyrolysis of 8,9-dihydro-14h-tetrazolo[1,5a]dibenzo[c,f]azonine and 6,7,8,9-tetrahydro- tetrazolo[1,5a]benzo[c]azocine

The flow-vacuum pyrolysis (FVP) of 8,9-dihydro-14H-tetrazolo[1,5a] dibenzo[c,f]azonine (13) and 6,7,8,9-tetrahydrotetrazolo[ 1,5-a]benzo[c]azocine (14) in quartz tube, inert atmosphere, between 300-550°C in vacuum was investigated using GC/MS. The corresp

Palladium-promoted arylation of functionalised organolithium compounds via their zinc derivatives

The reaction of different functionalised organolithium compounds 2, 5, 8, and 13 [easily prepared by DTBB-catalysed lithiation of isochromane (1), phthalane (4), 2,3-dihydrobenzofuran (7) and 1-chloro-3,3-diethoxypropane (12), respectively] with an equimo

Synthesis of novel GABA uptake inhibitors. Part 6: Preparation and evaluation of N-Ω asymmetrically substituted nipecotic acid derivatives

In a previous series of potent GABA uptake inhibitors published from this laboratory, we noticed that asymmetry in the substitution pattern of the bis-aromatic moiety in known GABA uptake inhibitors such as 4 [1-(4,4-diphenyl-3-butenyl)-3-piperidinecarboxylic acid] and 5 [(R)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid] was beneficial for high affinity. This led us to investigate asymmetric analogues of known symmetric GABA uptake inhibitors in which one of the aryl groups has been exchanged with an alkyl, alkylene or cycloalkylene moiety as well as other modifications in the lipophilic part. The in vitro values for inhibition of [3H]-GABA uptake in rat synaptosomes was determined for each compound, and it was found that several of the novel compounds inhibit GABA uptake as potently as their known symmetrical reference analogues. Several of the novel compounds were also evaluated for their ability to inhibit clonic seizures induced by a 15 mg/kg (ip) dose of methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM) in vivo. Some of the compounds, for example 18 [(R)-1-(2-(((1,2-bis(2-fluorophenyl)ethylidene)amino)oxy)ethyl)-3- piperidinecarboxylic acid], show a high in vivo potency and protective index comparable with that of our recently launched anticonvulsant product, 5 [(R)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid], and may therefore serve as second-generation drug candidates.

Negishi cross-coupling with functionalised organozinc compounds prepared by lithium-zinc transmetallation

The reaction of some functionalised organolithium compounds 2 (easily prepared by DTBB-catalysed lithiation of isochroman, phthalan and 2,3-dihydrobenzofuran) with an equimolecular amount of zinc bromide followed by reaction with an aryl or alkenyl bromide in the presence of a catalytic amount of Pd(PPh3)4 or Pd(PPh3)2(OAc)2 (5 mol%) under THF reflux overnight gave the expected cross-coupling compounds. These arylation or alkenylation processes, which work also with iodinated substrates, are not possible in the absence of the zinc or palladium compounds under the same reaction conditions.

Heterocyclic chemistry

The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.